RecruitingPhase 2NCT06513949

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Anti-CD14 Treatment With a Recombinant Chimeric Monoclonal Antibody (IC14) in Hospitalized Patients With Acute Respiratory Distress Syndrome

Sponsor

Implicit Bioscience

Enrollment

56 participants

Start Date

Jun 17, 2026

Study Type

INTERVENTIONAL

Conditions

Acute Lung Injury Acute Respiratory Distress Syndrome Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)Adult Respiratory Distress Syndrome

Summary

Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Atibuclimab and Placebo for people with acute lung injury, acute lung injury/acute respiratory distress syndrome (ards), and other related conditions. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.